Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423130 | 0.75 | HTR2A (0.34) | CHRNB4CHRNA3MEN1KMT2ALMNA | |
| SCHEMBL6076273 | 0.75 | ALDH1A1 (0.33) | CHRNB4CHRNA3MEN1KMT2ALMNA | |
| SCHEMBL18977551 | 0.73 | PRCP (0.47) | MEN1KMT2ALMNAMAPTGAA | |
| Hydrochloric Acid SCHEMBL4630224 | 0.73 | TSHR (0.32) | GAA | |
| SCHEMBL27499376 | 0.71 | MEN1 (0.31) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL5968223 | 0.71 | JAK2 (0.35) | — | |
| SCHEMBL28110816 | 0.70 | CHRNB4 (0.37) | CHRNB4CHRNA3MEN1KMT2ALMNA | |
| SCHEMBL20594416 | 0.69 | TSHR (0.50) | MAPTGAA | |
| SCHEMBL22891104 | 0.69 | MEN1 (0.37) | MEN1KMT2AMAPT | |
| SCHEMBL20594442 | 0.68 | ATM (0.36) | LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292630-A1 | O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-03-09 | — | — | EP | disclosed |
| CN-100398524-C | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1835931-A | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-7045526-B2 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040063690-A1 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-04-01 | — | — | US | disclosed |
| US-6660746-B1 | Cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1150963-B1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2003-12-03 | — | — | EP | disclosed |
| EP-1150963-A1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046214-A1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-10 | — | — | WO | disclosed |
| EP-0610439-B1 | PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PROD (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0610439-A1 | PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5234936-A | Treating hypertension, congestive heart failure, hyperlipidemia and hypercholesterolemia | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993008171-A1 | PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063690-A1 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | PDE3A, PDE2A, PDE3B | CHRNB4 4594/4885CHRNA3 4053/4885MEN1 3169/4885 |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | CHRNB4 316/4885CHRNA3 241/4885MEN1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.